ABSTRACT
Interstitial glucose monitoring systems are commonly being used in diabetic dogs. The aim of this study was to document the incidence of complications associated with the use of a flash glucose monitoring system (FGMS) in dogs. Medical records of dogs that had placement of a 14-day FGMS during a 1-year period were reviewed. Data retrieved included the number of days the sensor remained attached and functional, sensor detachment, sensor failure prior to the end of the 14-day monitoring period, and dermatologic changes at the sensor site. Descriptive statistics were used to characterize the data. Thirty-four dogs had FGMSs placed. Most [32/34 (94%)] sensors were placed over the dorsolateral aspect of the thorax caudal to the scapula. Twenty-four sensors (71%) remained attached for the full 14 days. Incidence of complications associated with FGMS use was 13/34 (38%). The most frequent complication was mild dermatologic changes at the sensor site [6/34 (18%)]. Erythema and crusting at the attachment site were common and could be related to contact dermatitis, hypersensitivity, or skin preparation prior to placement. Flash glucose monitoring systems are safe in dogs, although there are some potential complications that should be discussed with dog owners.
Les systèmes de surveillance du glucose interstitiel sont couramment utilisés chez les chiens diabétiques. Le but de cette étude était de documenter l'incidence des complications associées à l'utilisation d'un système de surveillance flash du glucose (FGMS) chez le chien. Les dossiers médicaux des chiens qui ont eu la mise en place pendant 14 jours d'un FGMS au cours d'une période d'un an ont été examinés. Les données récupérées comprenaient le nombre de jours pendant lesquels le capteur est resté attaché et fonctionnel, le détachement du capteur, la défaillance du capteur avant la fin de la période de surveillance de 14 jours et les changements dermatologiques au site du capteur. Des statistiques descriptives ont été utilisées pour caractériser les données. Trente-quatre chiens ont eu des FGMS placés. La plupart [32/34 (94 %)] des capteurs ont été placés sur la face dorsolatérale du thorax caudal à l'omoplate. Vingt-quatre capteurs (71 %) sont restés attachés pendant les 14 jours complets. L'incidence des complications associées à l'utilisation du FGMS était de 13/34 (38 %). La complication la plus fréquente était de légers changements dermatologiques au niveau du site du capteur [6/34 (18 %)]. L'érythème et la formation de croûtes au site de fixation étaient courants et pouvaient être liés à une dermatite de contact, à une hypersensibilité ou à la préparation cutanée avant la mise en place. Les systèmes de surveillance flash de la glycémie sont sans danger pour les chiens, bien qu'il existe certaines complications potentielles qui devraient être discutées avec les propriétaires de chiens.(Traduit par Docteur Serge Messier).
Subject(s)
Diabetes Mellitus , Dog Diseases , Dogs , Animals , Glucose , Blood Glucose Self-Monitoring/veterinary , Blood Glucose , Diabetes Mellitus/veterinary , Monitoring, Physiologic/veterinary , Monitoring, Physiologic/methodsABSTRACT
OBJECTIVES: Glucose monitoring is an integral part of diabetes management. Interstitial glucose monitoring systems are increasingly commonly being used for this purpose in dogs and cats, including the use of a flash glucose monitoring system (FGMS). The aim of this study was to describe the incidence and nature of complications associated with the use of an FGMS in diabetic cats. METHODS: The medical records of all cats that had placement of a 14-day FGMS during a 1-year period were retrospectively reviewed. Data retrieved included the number of days the sensor remained attached and functional, location of sensor placement and complications associated with the sensor. Complications were defined as early sensor detachment, sensor failure prior to the end of the 14-day monitoring period and dermatologic changes at the sensor site. Descriptive statistics were used to characterize the data. RESULTS: Twenty cats had a total of 33 FGMSs placed. The majority (30/33 [91%]) of sensors were placed over the dorsolateral aspect of the thorax just caudal to the scapula. Twenty (61%) FGMSs remained attached and functional for the full 14 days. The overall incidence of complications associated with FGMS use was 10/33 (30%). The most frequent complication was early sensor detachment (n = 5/33 [15%]). Mild dermatologic changes (erythema, crusts) were noted with 4/33 (12%) FGMSs. More serious complications (skin erosions, abscess formation) were noted with 2/33 (6%) FGMSs. CONCLUSIONS AND RELEVANCE: The use of the FGMS is relatively safe in cats, although there are potential complications that owners should be made aware of.
Subject(s)
Cat Diseases , Diabetes Mellitus , Dog Diseases , Animals , Blood Glucose , Blood Glucose Self-Monitoring/veterinary , Cat Diseases/epidemiology , Cats , Diabetes Mellitus/veterinary , Dogs , Retrospective StudiesABSTRACT
This report describes the synthesis and preliminary biological characterization of novel fatty acid niacin conjugates and fatty acid salicylate conjugates. These molecular entities were created by covalently linking two bioactive molecules, either niacin or salicylic acid, to an omega-3 fatty acid. This methodology allows the simultaneous intracellular delivery of two bioactives in order to elicit a pharmacological response that could not be replicated by administering the bioactives individually or in combination. The fatty acid niacin conjugate 5 has been shown to be an inhibitor of the sterol regulatory element binding protein (SREBP), a key regulator of cholesterol metabolism proteins such as PCSK9, HMG-CoA reductase, ATP citrate lyase, and NPC1L1. On the other hand, the fatty acid salicylate conjugate 11 has been shown to have a unique anti-inflammatory profile based on its ability to modulate the NF-κB pathway through the intracellular release of the two bioactives.
